Most medications are dosed by body weight. Chemotherapy drugs are different — many are dosed by body surface area (BSA), measured in square meters (m²). The reason is pharmacological: a patient's BSA correlates more reliably with blood volume, cardiac output, and the rate at which the body processes cytotoxic drugs than weight alone does. Understanding how BSA is calculated — and why it matters — helps patients, caregivers, and nursing students make sense of oncology treatment plans.
This article is for educational purposes. All chemotherapy dosing is determined by qualified oncology providers following institutional protocols.
Several BSA formulas exist, and different institutions may use different ones. The two most widely used in oncology are:
The Mosteller formula is preferred for clinical and educational use because it's easier to calculate manually and produces results within 2% of the more complex DuBois formula for most patients. It requires only two inputs — height in centimeters and weight in kilograms — and a square root.
Once BSA is calculated, the drug dose is:
The "dose per m²" is specific to each chemotherapy agent and is set by clinical trial data and established protocols.
A patient is 170 cm tall and weighs 70 kg. The oncologist orders cisplatin at 75 mg/m².
This patient receives approximately 136–137 mg of cisplatin for this cycle. A patient of the same weight but 155 cm tall would have a BSA of approximately 1.74 m², receiving about 130 mg — a clinically meaningful 5% difference that BSA-based dosing accounts for and weight-based dosing would miss.
For reference, the average adult BSA is approximately 1.7–1.9 m², with most adults falling in this range. Values below 1.5 m² or above 2.2 m² are less common and may trigger protocol-specific dose adjustments at some centers.
1. Using pounds and inches without converting first.
The Mosteller formula requires kilograms and centimeters. Plugging in pounds and inches produces a nonsensical result. Convert weight first (lbs ÷ 2.205 = kg) and height (inches × 2.54 = cm) before calculating. This is the most common arithmetic error in BSA-based dosing.
2. Confusing BSA with BMI.
BMI (Body Mass Index) and BSA are completely different calculations used for different purposes. BMI = weight (kg) ÷ height (m)², and it's a screening tool for weight classification. BSA incorporates height and weight into a surface area measurement for pharmacological dosing. They are not interchangeable, and a high BMI does not mean a high BSA in any direct way.
3. Applying a maximum BSA cap inconsistently.
Some oncology protocols cap BSA at 2.0 m² to avoid overdosing in large patients, since drug metabolism doesn't scale linearly with BSA at extreme values. Others use actual BSA without a cap. Using a cap when the protocol doesn't specify one, or omitting it when required, changes the administered dose. Always verify whether a cap applies before finalizing the calculation.
1. Verifying chemotherapy doses as a nurse or pharmacist.
Independent double-checks of BSA-based chemotherapy doses are standard practice in oncology. The nurse preparing to administer the drug recalculates BSA and the resulting dose using the patient's current height and weight — not a historical measurement — before administration.
2. Patient education during treatment planning.
Patients often receive a document or verbal explanation of their treatment plan that includes their calculated BSA and the resulting doses. Understanding how the number was derived helps patients engage meaningfully with their care team and notice if something looks inconsistent across cycles.
3. Pediatric oncology dosing.
BSA-based dosing is particularly critical in pediatric oncology because children's physiological parameters vary far more dramatically with size than in adults. A 6-year-old and a 12-year-old may have the same weight but significantly different BSAs — and their chemotherapy doses need to reflect that difference.
Does BSA change over the course of chemotherapy?
Yes. Significant weight loss during treatment — common with certain regimens — reduces BSA and may require dose recalculation. Most protocols specify whether to recalculate at each cycle or hold the original BSA. Weight should be measured at each cycle, and any significant change flagged to the oncology team.
Why is BSA used instead of weight for chemotherapy?
Chemotherapy drugs have narrow therapeutic windows — too little is ineffective, too much is toxic. BSA provides a more accurate proxy for the physiological parameters that govern drug distribution and clearance (blood volume, renal and hepatic blood flow) than weight alone. The correlation isn't perfect, but it's stronger than weight-based dosing for most cytotoxic agents.
Are all chemotherapy drugs dosed by BSA?
No. Some agents are dosed by weight (mg/kg), some by fixed dose regardless of size, and some use BSA. Targeted therapies and immunotherapy drugs are increasingly dosed as fixed amounts. The dosing method depends on the drug's pharmacokinetics and how clinical trials were designed.
What is a normal BSA for an adult?
The average BSA for adult men is approximately 1.9 m²; for adult women, approximately 1.6 m². These are rough averages — individual values vary based on height and weight. Most BSA-based drug doses were developed using a reference BSA of around 1.73 m².
BSA translates a patient's physical dimensions into a physiologically meaningful dosing unit for drugs where precision is critical. The Mosteller formula — square root of (height × weight ÷ 3,600) — makes that calculation accessible with basic arithmetic.